Dr Bob DuBridge, CEO of Full Spectrum Genetics, commented: “We are very excited about having access to a sam®X system in our laboratory, since it will enable us to accurately measure the binding of our protein and peptide inhibitors to multi-spanning proteins, such as tetraspanners and GPCRs, on the surface of intact cells. Traditionally these measurements have been difficult to make on this class of cellular receptors, and we expect this technology will enable us to expand our development of biotherapeutics to include these important pharmaceutical targets.”
Managing Director of SAW Instruments, Dr Markus Perpeet, said: “We are delighted that FSG has chosen the sam®X biosensor for its antibody research and development programs, as well as to demonstrate the system’s powerful capabilities to other interested parties. We have had a similar arrangement in Boston for East Coast customers and this has already proved extremely popular. SAW will also be implementing a local West Coast Field Applications Scientist, who will be on-site to offer support and showcase the system to other researchers.”
As the newest member of the sam® family, the sam®X is optimized for higher throughput, having 8 sensors, and for on-line loading and binding of capture proteins. The elegant fluidics on sam®X also enables samples to be delivered to unique sensor positions or to common groups of 2, 4 or 8 sensors with the same sample or reagent.
To request a sam®X demonstration at FSG, or for more information about the SAW approach, please visit www.saw-instruments.com.